Search Result

Results for "

Targeted Degradation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ligands for Target Protein for PROTAC (102) Target Protein Ligand-Linker Conjugates (21) 17β-HSD (1) AAK1 (3) Acetyl-CoA Carboxylase (1) ADC Linker (2) ADC Payload (2) Akt (7) Amyloid-β (3) Anaplastic lymphoma kinase (ALK) (2) Androgen Receptor (24) Antibiotic (4) Antibody-Drug Conjugates (ADCs) (1) Antibody-Oligonucleotide Conjugates (AOCs) (1) Apoptosis (66) ASK1 (1) Atg8/LC3 (1) ATP Synthase (1) ATTECs (2) Aurora Kinase (10) AUTACs (8) Autophagy (21) AUTOTACs (8) Bacterial (6) Bcl-2 Family (8) BCL6 (1) Bcr-Abl (3) Biochemical Assay Reagents (5) Btk (13) ByeTAC (3) c-Met/HGFR (4) c-Myc (6) Cadherin (1) Calcium Channel (1) CaMK (3) Carbonic Anhydrase (2) Casein Kinase (6) Caspase (6) Cathepsin (1) CCR (2) CDK (31) Checkpoint Kinase (Chk) (2) Cholecystokinin Receptor (1) CRM1 (3) Cyclin G-associated Kinase (GAK) (2) Cyclophilin (2) Cytochrome P450 (4) DAPK (1) Dengue Virus (1) Deubiquitinase (4) DNA Methyltransferase (2) DNA/RNA Synthesis (6) Drug Derivative (1) Drug Intermediate (2) Drug Metabolite (3) E1/E2/E3 Enzyme (10) E3 Ligase Ligand-Linker Conjugates (17) Early 2 Factor (E2F) (2) EGFR (17) Endogenous Metabolite (1) Endothelin Receptor (1) Ephrin Receptor (2) Epigenetic Reader Domain (74) Epoxide Hydrolase (3) ERK (5) Estrogen Receptor/ERR (14) FAK (4) Fc Receptor (FcR) (1) Ferroportin (1) Ferroptosis (16) FGFR (6) FKBP (8) FLT3 (7) GLUT (1) Glutaminase (2) Glutathione Peroxidase (7) GSK-3 (1) HBV (4) HCV (1) HDAC (20) Hedgehog (1) Herbicide (2) Hexokinase (1) HIF/HIF Prolyl-Hydroxylase (5) Histone Acetyltransferase (4) Histone Demethylase (3) Histone Methyltransferase (15) HIV (5) HSP (5) HuR (2) IAP (2) IFNAR (2) IGF-1R (1) IKK (2) IKZF Family (4) Indoleamine 2,3-Dioxygenase (IDO) (3) Insulin Receptor (1) Interleukin Related (5) IRAK (5) Isotope-Labeled Compounds (1) Itk (4) JAK (5) JNK (2) Keap1-Nrf2 (4) Kinesin (1) Ligands for E3 Ligase (17) LIM Kinase (LIMK) (4) Liposome (1) LRRK2 (1) LYTACs (5) MAGL (1) MALT1 (2) MAP3K (1) MAP4K (9) MAPKAPK2 (MK2) (1) MDM-2/p53 (9) MEK (4) MELK (1) MetAP (1) Mitochondrial Metabolism (1) Mitophagy (2) Mixed Lineage Kinase (1) Molecular Glues (43) Mps1 (2) mTOR (2) NAMPT (2) NEKs (2) NF-κB (8) NOD-like Receptor (NLR) (2) Nuclear Factor of activated T Cells (NFAT) (1) Nucleoside Antimetabolite/Analog (1) Oxysterol-binding Protein-related Protein (ORP) (1) p38 MAPK (9) p62 (1) p97 (2) PAK (1) Parasite (3) PARP (6) PCSK9 (1) PD-1/PD-L1 (5) PERK (2) Phytohormone (1) PI3K (6) PIN1 (1) Polo-like Kinase (PLK) (1) Potassium Channel (1) PPAR (2) Pregnane X Receptor (PXR) (3) Prion Protein (1) Programmed Cell Death 4 (PDCD4) (2) Prostaglandin Receptor (1) PROTAC Linkers (10) PROTAC-Linker Conjugates for PAC (1) PROTACs (339) Proteasome (4) Pyroptosis (2) Quinone Reductase (1) Raf (5) RANKL/RANK (1) Ras (17) Reactive Oxygen Species (ROS) (4) Reference Standards (5) RET (4) Ribosomal S6 Kinase (RSK) (1) RIP kinase (4) ROR (1) ROS Kinase (1) Salt-inducible Kinase (SIK) (3) SARS-CoV (6) Ser/Thr Kinase (2) Ser/Thr Protease (1) SF3B1 (1) Sirtuin (1) Small Interfering RNA (siRNA) (3) SNIPERs (4) SOS1 (3) Src (1) STAT (10) STING (4) SWI/SNF Complex (3) Syk (1) Tau Protein (3) Telomerase (1) TGF-beta/Smad (1) TNF Receptor (3) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (2) TRP Channel (1) ULK (4) VDAC (1) Virus Protease (4) WDR5 (3) Wee1 (3) Wnt (4) YAP (5) α-synuclein (4) β-catenin (4)
By Research Areas:	Cancer (608) Cardiovascular Disease (6) Endocrinology (4) Infection (23) Inflammation/Immunology (34) Metabolic Disease (15) Neurological Disease (30)
Click Chemistry:	PROTAC Synthesis (9) Azide (18) Alkynes (5)
Oligonucleotides:	Nucleoside Phosphoramidites (1) Adenine (1) siRNA drugs (1) Antisense Oligonucleotides (3) siRNAs (1)

706

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Target Protein Ligand-Linker Conjugates Ligands for Target Protein for PROTAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134592

Piperidine-GNE-049-N-Boc	Ligands for Target Protein for PROTAC	Cancer
Piperidine-GNE-049-N-Boc is a *ligand for target* protein for PROTAC** of dCBP-1 (HY-134582). dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-146324

PROTAC eEF2K degrader-1	PROTACs Apoptosis CaMK	Cancer
PROTAC eEF2K degrader-1 (Compound 11l) is an *eEF2K*-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells. PROTAC eEF2K degrader-1 mediates eEF2K degradation .

HY-174225

sEH-H ligand 1	Ligands for Target Protein for PROTAC Epoxide Hydrolase	Others
sEH-H ligand 1 is a PROTAC target protein ligand that can be used to synthesize PROTAC sEH degrader-2 (HY-174443) .

HY-174877

PROTAC HDAC6 degrader 6	PROTACs HDAC	Cancer
PROTAC HDAC6 degrader 6 (Compound 12) is a selective *HDAC6*-targeting photochemically targeting chimeras (PHOTACs) (subset of PROTAC) degrader with a ∼50% D_max only upon activation to its cis-state with 390 nm light irradiation . Pink: HDAC6 ligand; Blue: CRBN ligase ligand (HY-A0003); Black: linker

HY-157763

Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1	PROTAC-Linker Conjugates for PAC Transmembrane Glycoprotein	Cancer
Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 (Compound 3) is a "linker-payload" component of an antibody-drug conjugate (ADC). Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 selectively delivers the dual-function BTK degrader to B-cell malignancies by targeting the monoclonal antibody of CD79b. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be coupled to the engineered CD79b antibody with cysteine, forming CD79b-3 ADC (ADC linker: (HY-130944); Protac: (HY-163295)).

HY-168275

TRIB2 ligand-1	Ligands for Target Protein for PROTAC	Cancer
TRIB2 ligand-1 is a ligand of TRIB2 (*Ligands for Target* Protein for PROTACs*). TRIB2 ligand-1 can be used for synthesis PROTAC TRIB2 degrader*-1 (HY-168274) .

HY-162411

E3 ligase Ligand 24	Others	Cancer
E3 ligase Ligand 24 (Compound 24) is a Potent Ligand for the E3 Ligase DCAF15 (IC₅₀= 0.053 μM). Due to E3 ligase Ligand 24’s selectivity and potent binding characteristics, it is pivotal in the study of targeted protein degradation .

HY-141486A

PROTAC PARP/EGFR ligand 1	PARP EGFR Ligands for Target Protein for PROTAC	Others
PROTAC PARP/EGFR ligand 1 is an active compound that can be used for the synthesis of dual PARP EGFR degraders by proteolytic targeting chimera (PROTAC) technology .

HY-157512

SJF-0661	Ligands for E3 Ligase	Cancer
SJF-0661 is a variant of the von Hippel-Lindau (VHL) protein ligand with no targeted degradation ability and can be used as a control reagent for the VHL ubiquitin ligase ligand. SJF-0661 is a variant obtained by inverting the stereocenter of the key hydroxyproline group in the VHL ligand .

HY-168702

FLT3 ligand-2	Ligands for Target Protein for PROTAC	Cancer
FLT3 ligand-2 is a *Ligand for Target* Protein for PROTAC*. FLT3 ligand-2 can be used to synthesize PROTAC FLT-3 degrader* 1 (HY-114323) .

HY-175144

KRASG12D-IN-6	Ligands for Target Protein for PROTAC Ras	Cancer
KRASG12D-IN-6 is a PROTAC target protein ligand that can be used to synthesize CH091138 (HY-175025). CH091138 is a potent and selective KRASG12D PROTAC degrader with anti-tumor activity .

HY-157213

LWY713	Apoptosis PROTACs FLT3	Cancer
LWY713 is a PROTAC-class FLT3 degrader (DC₅₀=0.64 nM), which selectively induces FLT3 degradation via cereblon and proteasome-dependent pathways. LWY713 inhibits cell proliferation and induces G0/G1 phase arrest and apoptosis in MV4-11 cells. LWY713 shows effective in vivo antitumor activity in MV4-11 xenograft models . LWY713 consists of a target protein ligand (red part) Gilteritinib (HY-12432), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC linker (black part) Glycolic acid (HY-W015967). E3 ubiquitin ligase and linker can form Lenalidomide-Glycolic acid (HY-169373); the active control for the target protein ligand is Naproxen Gilteritinib (HY-169374).

HY-141881

PROTAC-O4I2	PROTACs Apoptosis SF3B1	Cancer
PROTAC-O4I2 is a PROTAC targets splicing factor 3B1 (SF3B1). PROTAC-O4I2 induces FLAG-SF3B1 degradation with an IC₅₀ value of 0.244 μM in K562 cells. PROTAC-O4I2 also induces cellular apoptosis in K562 WT cells .

HY-176786

MCB-36	PROTACs Ras Apoptosis PERK p38 MAPK Caspase TNF Receptor	Cancer
MCB-36 is a VHL-recruiting pan-KRAS PROTAC degrader without affecting KRAS transcription. MCB-36 exhibits minimal effects on HRAS and NRAS protein levels. MCB-36 binds to the GDP-loaded state of G12D, G12C, G12V, and wild-type KRAS with high affinities K_d ≈ 1 pM). MCB-36 decreases p-ERK levels, leading to cell apoptosis. MCB-36 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-36 can be used for the study of colorectal cancer and lung cancer (Pink: Target protein ligand; Blue: E3 ligand (HY-112078); Black: Linker (HY-W091879)) .

HY-145947

PROTAC BRD9 Degrader-5	PROTACs	Cancer
PROTAC BRD9 Degrader-5 is a PROTAC for targeted degradation of BRD9.

HY-153880

KRAS degrader-1	PROTACs Ras	Cancer
KRAS degrader-1 (compound 1) is a potent KRAS degrader. KRAS degrader-1 target specific proteins for degradation through the autophagy-lysosomal degradation pathway .

HY-173135

PROTAC KDM4 degrader-1	PROTACs Histone Demethylase Apoptosis	Cancer
PROTAC KDM4 degrader-1 (Compound 11) is a **KDM4-targeted proteolysis targeting chimeras (PROTAC) degrader*. PROTAC KDM4 degrader-1 can degrade* KDM4A-C while sparing KDM4D. PROTAC KDM4 degrader-1 exhibits potent antiproliferative activity in esophageal cancer cells. PROTAC KDM4 degrader-1 induces apoptosis and cell cycle arrest, and inhibits histone H3 lysine demethylation. (Blue: E3 ligase ligand (HY-112078), Black: linker (HY-W013381); Pink: ligand for target protein (HY-173136) ) .

HY-134725

MTH1 degrader-1	DNA/RNA Synthesis Ligands for Target Protein for PROTAC	Cancer
MTH1 degrader-1, a MTH1 aTAG inhibitor, is a PROTAC target protein ligand (*Ligand for Target* Protein for PROTAC*). MTH1 degrader*-1 can be used for synthesis PROTAC aTAG 4531 (HY-163168) .

HY-115728

PROTAC CDK9 degrader-4	PROTACs	Cancer
PROTAC CDK9 degrader-4 is a highly potent and efficacious CDK9 degrader for targeting transcription regulation.

HY-168055

(S)-Deoxy-thalidomide	Ligands for E3 Ligase	Cancer
(S)-Deoxy-thalidomide is an E3 ubiquitin ligase ligand. (S)-Deoxy-thalidomide can be linked to the target protein ligand through a linker to form PROTAC K-Ras Degrader-3 (HY-168054). PROTAC K-Ras Degrader-3 can target KRAS mutant proteins for degradation .

HY-152145

PROTAC SOS1 degrader-3	PROTACs Ras	Cancer
PROTAC SOS1 degrader-3 is a potent PROTAC SOS1 degrader. PROTAC SOS1 degrader-3 effectively targeted SOS1 for degradation through the ubiquitin-proteasome system .

HY-149964

PROTAC CDK9 degrader-7	PROTACs CDK	Cancer
PROTAC CDK9 degrader-7 is a PROTAC targeting to CDK9 sepcifically. PROTAC CDK9 degrader-7 mediates CDK9 degradation via the proteasome .

HY-168965

BTK ligand 15	Ligands for Target Protein for PROTAC	Others
BTK ligand 15 is the target protein ligand of PROTAC BTK Degrader-13 (HY-168963). PROTAC BTK Degrader-13 can selectively degrade BTK .

HY-173369

PROTAC MAGL degrader-1	PROTACs MAGL	Cancer
PROTAC MAGL degrader-1 is an orally active PROTAC agent that simultaneously targets monoacylglycerol lipase (MAGL) and E3 ubiquitin ligase MDM2. PROTAC MAGL degrader-1 degrades MAGL and inhibits the binding of MDM2 to p53. PROTAC MAGL degrader-1 can partially penetrate the blood-brain barrier (BBB). PROTAC MAGL degrader-1 induces glioblastoma stem cells (GSCs) apoptosis. (E3 ligase ligand: HY-128837; target protein ligand + linker: HY-173370; target protein inhibitor: HY-15249) .

HY-130614

PROTAC EED degrader-1	PROTACs Histone Methyltransferase	Cancer
PROTAC EED degrader-1 is a von Hippel-Lindau-based PROTAC targeting EED with a pK_D of 9.02. PROTAC EED degrader-1 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC₅₀=8.17) targeting the EED subunit .

HY-130615

PROTAC EED degrader-2 1 Publications Verification	PROTACs Histone Methyltransferase	Cancer
PROTAC EED degrader-2 is a von Hippel-Lindau-based PROTAC targeting EED with a pK_D of 9.27. PROTAC EED degrader-2 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC₅₀=8.11) targeting the EED subunit .

HY-149679

PROTAC eDHFR Degrader-2	PROTACs Bacterial	Cancer
PROTAC eDHFR Degrader-2 (compound 7b) is a potent degrader targeting Escherichia coli dihydrofolate reductase (eDHFR), enabling robust degradation of eDHFR-tagged proteins .

HY-173372

PROTAC AR Degrader-10	Androgen Receptor PROTACs	Cancer
PROTAC AR Degrader-10 is a protein degrader targeting the androgen receptor (AR) with a DC₅₀ value ≤100 nM. PROTAC AR Degrader-10 can be used for prostate cancer study. (Structure Note: Pink: target protein ligand (HY-173373); Blue: E3 ligase ligand (HY-138793); Black: linker) .

HY-168056

KRAS ligand 5	Others	Others
KRAS ligand 5 is the target protein ligand for PROTAC K-Ras Degrader-3 (HY-168054). PROTAC K-Ras Degrader-3 can specifically degrade KRAS mutated proteins .

HY-175652

PROTAC Androgen receptor degrader-1	PROTACs Androgen Receptor	Cancer
PROTAC Androgen receptor degrader-1 (Ex.14) is a PROTAC degrader targeting the androgen receptor with a DC₅₀ of 6 nM. PROTAC Androgen receptor degrader-1 is used in prostate cancer research. (Structure Note: Pink: target protein ligand (HY-175654); Blue: E3 ligase ligand (HY-175654); Black: linker) .

HY-163640

CDK4 degrader 1	Molecular Glues CDK	Cancer
CDK4 degrader 1 (ML 1–71) is a molecular glue degrader that targets CDK4 .

HY-174238

GSPT1 degrader-7	Molecular Glues	Cancer
GSPT1 degrader-7 (Example 43) is a molecular glue degrader targeting GSPT1. GSPT1 degrader-7 has an EC₅₀ of 0.2 nM in DF15 multiple myeloma cells. GSPT1 degrader-7 can be used in the study of cancer .

HY-168624

VAV1 degrader-2	Molecular Glues	Inflammation/Immunology
VAV1 degrader-2 (Example 176) is a molecular glue degrader based on targeting VAV 1 with a DC₅₀ of 4.41 nM. VAV1 degrader-2 can be used in the study of inflammatory and autoimmune diseases .

HY-163638

BRD4 degrader-1	Molecular Glues Epigenetic Reader Domain E1/E2/E3 Enzyme	Cancer
BRD4 degrader-1 (Compound ML 1-50) is a monovalent and covalent molecular glue BRD4 degrader. BRD4 degrader-1 targets DCAF16 (E3 ligase) and degrades both the long and short isoforms of BRD4 in cells .

HY-159662

HSD17B13 degrader 2	Ligands for Target Protein for PROTAC	Cancer
HSD17B13 degrader 2 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). HSD17B13 degrader 2 can be used for synthesis PTOTAC HSD17B13 degrader 1 (HY-159651) .

HY-168017

NSC682769	Ligands for Target Protein for PROTAC	Cancer
NSC682769 is a PROTAC target protein ligand (*Ligands for Target* Protein for PROTACs*). NSC682769 can be used for synthesis PROTAC YAP degrader*-1 (HY-168016) .

HY-161108

PROTAC Chk1 degrader-1	PROTACs Checkpoint Kinase (Chk)	Cancer
PROTAC Chk1 degrader-1 (Compound PROTAC-2 ) is a potent PROTAC-targeted degrader of Chk1 with a DC₅₀ of 1.33 μM. PROTAC Chk1 degrader-1 can be used in cancer research .

HY-169343

FIZ1 degrader 1	Molecular Glues	Cancer
FIZ1 degrader 1 (compound 1) is an IMiD-based molecular glue degrader targeting FIZ1 .

HY-112557

PROTAC TBK1 degrader-2	PROTACs IKK	Cancer
PROTAC TBK1 degrader-2 is a *Ligands for Target* Protein for PROTAC*. PROTAC TBK1 degrader-2 is a potent degrader* based on the serine/threonine kinase TANK-binding kinase 1 (TBK1) (DC₅₀=15 nM; K_d=4.6 nM) with a maximum efficiency of 96%. PROTAC TBK1 degrader-2 also targets to IkB kinase IKKε (IC₅₀=8.7 nM), with low selectivity over TBK1 (IC₅₀=1.3 nM) .

HY-163874

PROTAC SMARCA2 degrader-12	PROTACs	Cancer
SMARCA2 degrader-13 (compound I-406) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an DC₅₀ <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-163866

PROTAC SMARCA2 degrader-14	PROTACs	Cancer
SMARCA2 degrader-3 (compound I-323) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an DC₅₀ <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-163867

PROTAC SMARCA2 degrader-15	PROTACs	Cancer
SMARCA2 degrader-4 (compound I-332) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an DC₅₀ <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-163865

PROTAC SMARCA2 degrader-13	PROTACs	Cancer
SMARCA2 degrader-2 (compound I-322) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an DC₅₀ <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-172162

LC-04-045	NEKs Interleukin Related	Inflammation/Immunology
LC-04-045 is a NEK7 (NIMA-related kinase 7) molecular glue degrader (MGD). LC-04-045 demonstrates potent activity of NEK7 degradation with a DC₅₀ (half-maximal degradation) of 7 nM and a D_max (maximum degradation) of 90% in MOLT-4 cells. LC-04-045 displays high selectivity for NEK7 across the proteome. LC-04-045 degrades NEK7 mediated by the ubiquitin-proteasome system (UPS) and relies on the glycine 57 (G57)-containing degron motif in NEK7. LC-04-045 effectively inhibits secretion of IL-1β and IL-18 with IC₅₀s of 33.03 nM and 32.99 nM, respectively. LC-04-045 is potential for inflammatory diseases research .

HY-161795

SP3CHO	Drug Metabolite	Cancer
SP3CHO is an active metabolite generated by the metabolism of SP3N in cell culture by the action of amine oxidase. SP3CHO can induce polyubiquitination of specific proteins by recruiting the SCFFBXO22 E3 ligase complex. SP3CHO can be used in cancer therapy research .

HY-159894

Autophagy-lysosome activator-1	Autophagy	Cancer
Autophagy-lysosome activator-1 (Compound F1) is a Autophagy-lysosome activator. Autophagy-lysosome activator-1 effectively induces PD-L1 or VISTA degradation in tumor cells .

HY-11103

Sitaxsentan sodium 1 Publications Verification IPI 1040 sodium; TBC11251 sodium	Endothelin Receptor	Cardiovascular Disease Endocrinology
Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally activeendothelin A receptor (ET_A) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan sodium exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium inhibits ET-1-induced phosphoinositide turnover. Sitaxsentan sodium can significantly alleviate pulmonary arterial hypertension (PAH) symptoms. Sitaxsentan sodium can be used for the study of PAH .

HY-171768

SK2187 JB301	PROTACs Aurora Kinase	Neurological Disease Cancer
SK2187 is a selective AURKA PROTAC degrader with a DC₅₀ of about 10 nM. SK2187 exhibits growth inhibition against NGP cells with an IC₅₀ of 101.5 nM. SK2187 can be used for the study of MYCN-amplified neuroblastoma (Pink: AURKA ligand: MK-5108 (HY-13252); Blue: E3 ligand (HY-103597); Black: Linker: Amino-PEG3-alcohol (HY-W015088)) .

HY-170341

ER ligand-6	Ligands for Target Protein for PROTAC Estrogen Receptor/ERR	Cancer
ER ligand-6 is a target protein ligand of PROTAC ER Degrader-14 (HY-170340) .

HY-162747

PROTAC SMARCA2 degrader-17	PROTACs	Cancer
PROTAC SMARCA2 degrader-17 (compound I-290) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an DC₅₀ <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

Cat. No.	Product Name

HY-L151

PROTAC Library

416 compounds

PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy.

MCE supplies a unique collection of 416 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.

HY-L137

Molecular Glue Compound Library

74 compounds

Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention.

Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy.

MCE supplies a unique collection of 74 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

HY-L129

Target Protein Ligand Library

69 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 69 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

HY-L918

Molecular Glue-like Compound Library

318 compounds

Targeted Protein Degradation (TPD) is a novel and promising approach to drug development. It shows great potential for targeting proteins traditionally considered "undruggable" due to the lack of enzymatic function and absence of binding sites by tagging them for degradation or recruiting natural degradation mechanisms.

Molecular glues are a type of small-molecule degraders that primarily induce novel interactions between E3 ubiquitin ligases and target proteins, forming ternary complexes that lead to protein ubiquitination and subsequent proteasomal degradation. Compared with PROTACs, molecular glues generally have lower molecular weights, higher cell permeability, and better drug-like properties. Additionally, the design of molecular glues is relatively simple, without the requirements for complex linkers and ligand optimization. As a result, molecular glues have gradually emerged as a promising therapeutic approach for various diseases.

Multiple types of molecular glues have been reported previously. Analysis of co-crystal complex structures reveals that CRBN-related molecular glues are more versatile. Therefore, MCE researchers select active molecules related to these targets as probes for artificial intelligence (AI) screening.Subsequently, molecular docking technology was used to verify whether the screened molecules retained the key pharmacophore features. Ultimately, we obtained 320 molecular glue analogs, and these compounds serve as powerful tools for the research of molecular glues.

HY-L128

E3 Ligase Ligand Library

94 compounds

Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).

MCE carefully prepared a unique collection of 94 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

HY-L214

Liposome Library

138 compounds

Liposomes are spherical or multilayered spherical vesicles formed by the self-assembly of diacyl chain phospholipids (lipid bilayers) in aqueous solutions, which can be made from natural or synthetic phospholipids and exhibit good biocompatibility and low toxicity. They can serve as delivery carriers for various bioactive substances (such as drugs, proteins, nucleic acids, etc.) and are widely used in biomedical and chemical research. The main advantages of liposomes include 1) Protective effect: Their bilayer structure can protect encapsulated molecules from enzymatic degradation, oxidation, and other influences, extending stability and activity; 2) Active targeting: Surface modifications enable active targeting, enhancing the concentration of drugs or molecules in specific tissues or cells; 3) Customizability: The composition and structure of liposomes can be adjusted according to needs, such as altering phospholipid types or adding targeting ligands. These properties make liposomes highly valuable in developing novel drug delivery systems, serving as nucleic acid carriers for gene transfection, studying cellular uptake mechanisms and drug release kinetics, as well as developing functional food additives to improve the bioavailability of nutritional components.

MCE contains 138 liposome compounds, which is a good tool for lipidomic-related studies.

HY-L050

Ubiquitination Compound Library

368 compounds

Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc.

MCE offers a unique collection of 368 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

HY-L140

Withdrawn Drug Compound Library

228 compounds

Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug.

Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications.

MCE has sorted out 228 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

HY-L045

Oxygen Sensing Compound Library

3,451 compounds

Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression.

Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival.

HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation.

MCE offers a unique collection of 3,451 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Cat. No.	Product Name	Type

HY-D2259

PFI-7	Fluorescent Dyes/Probes
PFI-7 is a probe, which binds to human GID4 (K_D is 79 nM), and antagonizes the binding of Pro/N-degrons. PFI-7 can be utilized in C-terminal to LisH (CTLH) complex research and development of targeted protein degradation .

Cat. No.	Product Name	Type

HY-158228

Poly-L-lysine Methacryloyl

PLMA

3D Bioprinting

Poly-L-lysine Methacryloyl (PLMA) is methacrylated polylysine. When Poly-L-lysine Methacryloyl is cross-linked on polyetheretherketone (PEEK) through UV-induced cross-linking, it can improve the hydrophilicity of PEEK and retain its own degradation bioinertness . Poly-L-lysine Methacryloyl needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc.

HY-158221

Chondroitin Sulfate Methacryloyl

CSMA

3D Bioprinting

Chondroitin Sulfate Methacryloyl (CSMA) is methacrylated chondroitin sulfate and is biocompatible. Chondroitin Sulfate Methacryloyl has a higher degree of methacrylation than HAMA (HY-158220), and the degree of methacrylation is closely related to customizable mechanical properties, swelling properties and enzymatic degradability. Chondroitin Sulfate Methacryloyl is a versatile biomaterial suitable for biomimetic hydrogel scaffolds and an ideal 3D printing hydrogel ink . Chondroitin Sulfate Methacryloyl needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc.

HY-112624H

Dextran T2 (MW 2,000)

Dextran 2; Dextran D2; Dextran T2(MW 1600-2400)

Thickeners

Dextran T2 (Dextran 2; Dextran T2(MW 1600-2400)) is a natural high molecular weight polysaccharide, the glycosidic bonds in its structure can be recognized by endo-dextranase and exo-dextranase. Dextran T2 (MW 2,000) breaks the glycosidic bonds in the enzymatic hydrolysis mechanism, releasing products such as D-glucose, Isomaltose (IM₂), and Isomaltotriose (IM₃). Dextran T2 (MW 2,000) can be used as a model substrate to characterize the catalytic properties of dextranase (such as optimal pH, temperature and product specificity), and to study enzymatic mechanism research and polysaccharide degradation pathways in glycobiology. The Dextran series of compounds are also a natural polysaccharide drug carrier, which can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity .

HY-W250129

2,3,4,5-Tetrafluorobenzoyl chloride

Biochemical Assay Reagents

2,3,4,5-Tetrafluorobenzoyl chloride is a fluorinated organic compound that belongs to the class of benzoyl chlorides. It is a colorless liquid with a pungent smell and is mainly used as an intermediate in the synthesis of various pharmaceutical and pesticide compounds. 2,3,4,5-Tetrafluorobenzoyl chloride is an acylating agent that can react with a variety of nucleophiles, including amines, alcohols, and thiols, to form amides, esters, or thioesters, respectively. Its unique fluorine-containing structure can impart desired properties to target molecules, such as increased lipophilicity or increased stability against metabolic degradation. However, due to its high reactivity and potential health hazards, proper safety measures and handling procedures must be followed when using this compound.

Cat. No.	Product Name	Target	Research Area

HY-P3717

Targefrin	Ephrin Receptor	Cancer
Targefrin is a potent *EphA2*-targeting agent, acts as an antagonist. Targefrin binds EphA2-LBD with 21 nM dissociation constant and an IC₅₀ value of 10.8 nM. Targefrin induces cellular receptor internalization and degradation in several pancreatic cancer cell lines .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-169235

DHHC3 ligand 1	Ligands for Target Protein for PROTAC	Cancer
DHHC3 degrader 1 is a PROTAC target protein ligand that is used to synthesize PCC16 chloride (HY-169232) .

HY-P11104

SsrA tag	Peptides	Others
SsrA tag is an 11-aa peptide added to the C-terminus of proteins stalled during translation, targeting them for degradation by ClpXP and ClpAP .

HY-P5277

TAT-GluN2BCTM	DAPK	Neurological Disease
TAT-GluN2BCTM is a membrane-permeable *DAPK1*-targeting peptide. TAT-GluN2BCTM targets active DAPK1 to lysosomes for degradation. TAT-GluN2BCTM protects neurons from oxidative stress and NMDAR-mediated excitotoxicity by knocking down DAPK1. TAT-GluN2BCTM can be used in the study of neuroprotection .

HY-169232

PCC16 chloride	PROTACs	Cancer
PCC16 chloride is a CRBN-based cp-PCC with an IC₅₀ value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .

HY-P11020

p27 Analogue CP2	E1/E2/E3 Enzyme	Cancer
p27 Analogue CP2 is a macrocyclic peptide inhibitor targeting the SCFSkp2/Cks1 E3 ubiquitin ligase (K_d=32 nM). p27 Analogue CP2 blocks SCFSkp2/Cks1-mediated ubiquitylation and degradation of p27, restoring p27 levels and inhibiting cell proliferation. p27 Analogue CP2 is promising for research of cancers dependent on Skp2 overexpression such as breast cancer .

HY-P5377

Abz-HPGGPQ-EDDnp Cathepsin K substrate	Ser/Thr Protease	Others
Abz-HPGGPQ-EDDnp (Cathepsin K substrate) is a biological active peptide. (Cathepsins are a class of globular lysosomal proteases, playing a vital role in mammalian cellular turnover. They degrade polypeptides and are distinguished by their substrate specificities. Cathepsin K is the lysosomal cysteine protease involved in bone remodeling and resorption. It has potential as a drug target in autoimmune diseases and osteoporosis.This FRET peptide can be used to monitor selectively cathepsin K activity in physiological fluids and cell lysates. Abz-HPGGPQ-EDDnp [where Abz represents o-aminobenzoic acid and EDDnp represents N -(2, 4-dinitrophenyl)-ethylenediamine], a substrate initially developed for trypanosomal enzymes, is efficiently cleaved at the Gly-Gly bond by cathepsin K. This peptide is resistant to hydrolysis by cathepsins B, F, H, L, S and V, Ex/Em=340 nm/420 nm.)

Cat. No.	Product Name	Target	Research Area

HY-P99672

Istiratumab MM 141; MM-005	IGF-1R EGFR	Cancer
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .

HY-P99009

Batoclimab RVT-1401; HBM9161; IMVT-1401	Fc Receptor (FcR)	Inflammation/Immunology
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .

HY-P991342

CQY684 PCA062 antibody	Cadherin	Cancer
CQY684 (PCA062 antibody) is a human monoclonal antibody (mAb) targeting CDH3/P-cadherin. CQY684 stabilizes the X-dimer of P-cadherin, promoting its endocytosis and directing it to lysosomal degradation. CQY684 can be used in Breast, esophageal, and head and neck cancers research .

HY-P991235

FS102 BMS-986186	EGFR Caspase	Cancer
FS102 is a selective Fc fragment with antigen binding (Fcab) that targets HER2 with a K_D value of 0.8 nM. FS102 induces the degradation of HER2, activates Caspase 3/7 and disrupts the integrity of the cell membrane, triggering apoptosis of tumor cells. FS102 is promising for research of cancers such as breast cancer, gastric cancer, and colorectal cancer .

HY-P991243

MP-RM-1	EGFR PI3K Akt	Cancer
MP-RM-1 is a selective murine monoclonal antibody inhibitor targeting human epidermal growth factor receptor 3 (ErbB-3). MP-RM-1 blocks the activation of ErbB-3 induced by neuregulin 1 (NRG-1β) and promotes the internalization and degradation of ErbB-3, inhibiting downstream signaling pathways such as PI3K-Akt. MP-RM-1 is promising for research of ErbB-3 highly expressed solid tumors such as breast cancer, melanoma, and prostate cancer .

HY-P991234

COVA208	EGFR p38 MAPK PI3K Akt	Cancer
COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive breast cancer, gastric cancer, and colorectal cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7449

Neamine	Infection Cardiovascular Disease Classification of Application Fields Disease Research Fields	Antibiotic Bacterial
Neamine, a degradation product of Neomycin, is a broad-spectrum aminoglycoside antibiotic. Neamine is an anti-angiogenesis agent targeting angiogenin. Neamine has potent antibacterial, antitumor and neuroprotective activities .

HY-N6929

Angelic acid	Ketones, Aldehydes, Acids Source classification Umbelliferae Plants Echinacea angustifolia DC.	Ferroptosis Keap1-Nrf2 Reactive Oxygen Species (ROS)
Angelic acid is a ferroptosis inducer, targeting NRF2 degradation. Angelic acid binds to NRF2 protein and promotes NRF2 degradation via ubiquitination-proteasome pathway, relieves the inhibitory effect of NRF2 on oxidative stress and lipid peroxidation. Then, Angelic acid induces ferroptosis in tumor cells. Angelic acid can enhance the accumulation of intracellular reactive oxygen species (ROS), upregulate ferroptosis-related markers CHAC1 and PTGS2, and synergize with ferroptosis inducers to enhance anti-tumor effects. Angelic acid also has the activity of scavenging UVA-induced ROS in vitro, inhibiting skin fibroblast senescence and extracellular matrix degradation. Angelic Acid helps wound healing with sedative activity .

HY-N0242

Fraxinellone 4 Publications Verification	Classification of Application Fields Terpenoids Dictamnus dasycarpus Turcz. Sesquiterpenes Source classification Rutaceae Plants Inflammation/Immunology Disease Research Fields	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 .

HY-N6769

Radicicol 3 Publications Verification Monorden	Antifungal Classification of Application Fields Marine natural products Source classification Anti-parasitic Disease Research Infection Microorganisms Macrolide Antibiotics Antibiotics Phenols Polyphenols Marine microorganism Disease Research Fields	HSP Bacterial Antibiotic Parasite
Radicicol is an inhibitor of Hsp90 with an IC₅₀ value < 1 μM, and leads to proteasomal degradation . Radicicol exhibits inhibition on PDK with IC₅₀s of 230 μM (PDK1) and 400 μM (PDK3). Radicicol is an antifungal and antimalarial antibiotic, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB . Radicicol is also an inhibitor of fat mass and obesity-associated protein (FTO), with an IC₅₀ value of 16.04 μM .

HY-N10568

Gibberellin A9	Malvaceae Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Plants Endogenous metabolite	Phytohormone
Gibberellin A9 is a plant hormone targeting gibberellin receptor GID1. Gibberellin A9 binds to GID1 to form a GA-GID1-DELLA protein complex, which promotes the degradation of DELLA proteins, thus relieving the inhibitory effect of DELLA proteins on plant growth, and then promoting plant cell elongation and division, as well as increasing the germination rate of seeds. Gibberellin A9 is promising for research of plant growth and development, such as stem elongation, flowering induction .

HY-W010041

Scyllo-Inositol	Natural Products Source classification Endogenous metabolite	α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N0696

Sipeimine 4 Publications Verification Imperialine	Alkaloids Piperidine Alkaloids Liliaceae Classification of Application Fields Source classification Other Diseases Fritillaria ussuriensis Maxim. Plants Disease Research Fields	PI3K NF-κB Akt NOD-like Receptor (NLR) Pyroptosis Ferroptosis
Sipeimine (Imperialine) is an inhibitor targeting the PI3K/AKT/NF-κB pathway and NLRP3 inflammasome, which can competitively bind to PI3K and p65. Sipeimine inhibits PI3K/AKT phosphorylation, blocks NF-κB nuclear translocation and NLRP3 inflammasome activation. Sipeimine exerts anti-inflammatory activities, inhibits pyroptosis and ferroptosis, and protects the extracellular matrix. Sipeimine can reduce cartilage degradation and synovial inflammation in osteoarthritis and improve PM2.5-induced lung injury. Sipeimine is mainly used in the study of anti-inflammatory and degenerative diseases .

HY-N6929R

Angelic acid (Standard)	Ketones, Aldehydes, Acids Source classification Umbelliferae Plants Echinacea angustifolia DC.	Reference Standards Ferroptosis Keap1-Nrf2 Reactive Oxygen Species (ROS)
Angelic acid (Standard)) is the analytical standard of Angelic acid (HY-N6929). This product is intended for research and analytical applications. Angelic acid is a ferroptosis inducer, targeting NRF2 degradation. Angelic acid binds to NRF2 protein and promotes NRF2 degradation via ubiquitination-proteasome pathway, relieves the inhibitory effect of NRF2 on oxidative stress and lipid peroxidation. Then, Angelic acid induces ferroptosis in tumor cells. Angelic acid can enhance the accumulation of intracellular reactive oxygen species (ROS), upregulate ferroptosis-related markers CHAC1 and PTGS2, and synergize with ferroptosis inducers to enhance anti-tumor effects. Angelic acid also has the activity of scavenging UVA-induced ROS in vitro, inhibiting skin fibroblast senescence and extracellular matrix degradation. Angelic Acid helps wound healing with sedative activity .

HY-N0242R

Fraxinellone (Standard)	Terpenoids Dictamnus dasycarpus Turcz. Sesquiterpenes Source classification Rutaceae Plants	Reference Standards PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Fraxinellone (Standard) is the analytical standard of Fraxinellone. This product is intended for research and analytical applications. Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 .

HY-W010041R

Scyllo-Inositol (Standard)	Natural Products Source classification Endogenous metabolite	α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N0696R

Sipeimine (Standard) Imperialine (Standard)	Alkaloids Piperidine Alkaloids Liliaceae Source classification Fritillaria ussuriensis Maxim. Plants	Reference Standards PI3K NF-κB Akt NOD-like Receptor (NLR) Pyroptosis Ferroptosis
Sipeimine (Standard) is the analytical standard of Sipeimine (HY-N0696R). Sipeimine (Imperialine) is an inhibitor targeting the PI3K/AKT/NF-κB pathway and NLRP3 inflammasome, which can competitively bind to PI3K and p65. Sipeimine inhibits PI3K/AKT phosphorylation, blocks NF-κB nuclear translocation and NLRP3 inflammasome activation. Sipeimine exerts anti-inflammatory activities, inhibits pyroptosis and ferroptosis, and protects the extracellular matrix. Sipeimine can reduce cartilage degradation and synovial inflammation in osteoarthritis and improve PM2.5-induced lung injury. Sipeimine is mainly used in the study of anti-inflammatory and degenerative diseases .

HY-W100287

Murrayafoline A	Alkaloids Murraya tetramera C. C. Huang Source classification Rutaceae Carbazole Alkaloids Plants	NF-κB p38 MAPK Interleukin Related IKK JNK β-catenin Wnt
Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer .

Cat. No.	Product Name	Chemical Structure

HY-176785S

MCB-294

MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with K_ds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC₅₀s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer .

HY-W707693

Scyllo-Inositol-d6

Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

Cat. No.	Product Name		Classification

HY-143904

PROTAC TTK degrader-1		PROTAC Synthesis
PROTAC TTK degrader-1 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 1.7 and 5.8 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-1 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

HY-174225

sEH-H ligand 1		Alkynes
sEH-H ligand 1 is a PROTAC target protein ligand that can be used to synthesize PROTAC sEH degrader-2 (HY-174443) .

HY-159462

PROTAC SMARCA2 degrader-10		Azide
PROTAC SMARCA2 degrader-10 (compound I-507) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an DC₅₀ <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159450

PROTAC SMARCA2 degrader-6		Azide
PROTAC SMARCA2 degrader-6 (compound I-427) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an DC₅₀ <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159458

PROTAC SMARCA2/4-degrader-7		Azide
SMARCA2/4-degrader-7 (compound I-439) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the DC₅₀s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159459

PROTAC SMARCA2/4-degrader-32		Azide
PROTAC SMARCA2/4-degrader-32 (compound I-446) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the DC₅₀s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159452

PROTAC SMARCA2/4-degrader-1		Azide
SMARCA2/4-degrader-1 (compound I-430) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the DC₅₀s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-159453

PROTAC SMARCA2/4-degrader-2		Azide
SMARCA2/4-degrader-2 (compound I-431) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the DC₅₀s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .

HY-143905

PROTAC TTK degrader-2		PROTAC Synthesis
PROTAC TTK degrader-2 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 3.1 and 12.4 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-2 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

HY-176795

SHP2 ligand-3		Alkynes
SHP2 ligand-3 is a PROTAC target protein ligand that can be used to synthesize SHP2 protein degrader-1 (HY-145159) .

HY-163926

SMARCA2/4-IN-2		Azide
SMARCA2/4-IN-2 is a PROTAC target protein ligand (*Ligands for Target* Protein for PROTACs*). SMARCA2/4-IN-2 can be used for synthesis PROTAC SMARCA2/4-degrader-5* (HY-159456) .

HY-159449

PROTAC SMARCA2 degrader-5		Azide
PROTAC SMARCA2 degrader-5 (Compound I-425) is a PROTAC degrader for catalytic subunit of the SWI/SNF complex SMARCA2. PROTAC SMARCA2 degrader-5 degrades SMARCA2 in MV411 and in A549 with DC₅₀ <100 nM, degrades SMARCA4 with DC₅₀ of 100-500 nM . (Pink: Ligand for target protein (HY-159531); Black: Linker (HY-159538); Blue: Ligand for E3 ligase (S,R,S)-AHPC (HY-125845))

HY-159461

PROTAC SMARCA2/4-degrader-9		Azide
PROTAC SMARCA2/4-degrader-9 (Compound I-503) is a PROTAC degrader for catalytic subunit of the SWI/SNF complex SMARCA2 and SMARCA4. PROTAC SMARCA2 degrader-9 degrades SMARCA2 in MV411 and in A549 with DC₅₀ <100 nM, degrades SMARCA4 in MV411 with DC₅₀ <100 nM . (Pink: Ligand for target protein (HY-159545); Black: Linker (HY-W006635); Blue: Ligand for E3 ligase (S,R,S)-AHPC (HY-125845))

HY-159451

PROTAC SMARCA2 degrader-7		Azide
PROTAC SMARCA2 degrader-7 (Compound I-428) is a PROTAC degrader for SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A (SMARCA) SMARCA2. PROTAC SMARCA2 degrader-7 degrades SMARCA2 and SMARCA4 in MV411 with DC₅₀ of <100 and 100-500 nM. (Pink: Ligand for target protein (HY-159542); Black: Linker (HY-159538); Blue: Ligand for E3 ligase (S,R,S)-AHPC (HY-125845))

HY-159455

PROTAC SMARCA2/4-degrader-4		Azide
PROTAC SMARCA2/4-degrader-4 (Compound I-434) is a PROTAC degrader for catalytic subunit of the SWI/SNF complex SMARCA2 and SMARCA4. PROTAC SMARCA2/4-degrader-4 degrades SMARCA2 in MV411 and in A549 with DC₅₀ <100 nM, degrades SMARCA4 in MV411 with DC₅₀ <100 nM. (Pink: Ligand for target protein (HY-159472); Black: Linker (HY-159478); Blue: Ligand for E3 ligase (S,R,S)-AHPC (HY-125845))

HY-159456

PROTAC SMARCA2/4-degrader-5		Azide
PROTAC SMARCA2/4-degrader-5 (Compound I-437) is a PROTAC degrader for catalytic subunit of the SWI/SNF complex SMARCA2 and SMARCA4. PROTAC SMARCA2/4-degrader-5 degrades SMARCA2 in MV411 and in A549 with DC₅₀ <100 nM, degrades SMARCA4 in MV411 with DC₅₀ of 100-500 nM. (Pink: Ligand for target protein (HY-159545); Black: Linker (HY-159557); Blue: Ligand for E3 ligase (S,R,S)-AHPC (HY-125845))

HY-159460

PROTAC SMARCA2/4-degrader-8		Azide
PROTAC SMARCA2/4-degrader-8 (Compound I-502) is a PROTAC degrader for catalytic subunit of the SWI/SNF complex SMARCA2. PROTAC SMARCA2/4-degrader-8 degrades SMARCA2 with DC₅₀ <100 nM in A549 and in MV411, degrades SMARCA4 with DC₅₀<100 nM in MV411(Pink: Ligand for target protein (HY-159545); Black: Linker (HY-W063924); Blue: Ligand for E3 ligase (S,R,S)-AHPC (HY-125845))

HY-172360

HDAC6 ligand-3		Alkynes
HDAC6 ligand-3 is a ligand for HDAC6 that can be used as target protein ligand for synthesis of PROTAC HDAC6 degrader 4 (HY-172359) .

HY-146231A

SS47 TFA		PROTAC Synthesis
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies . SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-150251

SD-91 STAT3 degrader-2		PROTAC Synthesis
SD-91 (STAT3 degrader-2), a product of the hydrolysis of SD-36 (HY-129602), is a selective PROTAC-based STAT3 degrader with a K_i of 5.5 nM. SD-91 displays >300-fold selectivity over other STAT family protein members. SD-91 potently induces degradation of STAT3 protein in cells. SD-91 has anticancer effects, such as myeloid leukemia, lymphoma (Pink: ligand for target protein (HY-150895); Black: linker; Blue: E3 ligase ligand; E3 ligase ligand+linker: HY-176506) .

HY-176785S

MCB-294		Alkynes
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with K_ds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC₅₀s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer .

HY-159087

RGB110		Azide
RGB110 (Compound 10d) is a PROTAC inhibitor for D-dopachrome tautomerase with an IC₅₀ of 5.9 μM. RGB110 causes no degradation of D-DT. (Pink: ligand for target protein (HY-159164); Black: linker (HY-W125017); Blue: ligand for E3 ligase CRBN (HY-10984))

HY-152261

MS6105		PROTAC Synthesis
MS6105 is an LDH protein hydrolysis-targeted chimera (PROTAC) that effectively degrades LDHA and LDHB in a time- and ubiquitin-proteasome system-dependent manner and has anticancer activity . MS6105 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-69220

7-Octynoic acid		PROTAC Synthesis Alkynes
7-Octynoic acid (compound 42) is a PROTAC linker and can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins . 7-Octynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-153665

Deg-1		Azide
Deg-1 is a a bifunctional probe with a cleavage group and a covalent binding group. Deg-1 covalently binds to the target nucleic acid, and serves as click-degrader to cleave a nucleic acid molecule. Deg-1 has potential to selectively cleave target nucleic acids in cells . It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

HY-114402

ARD-69		PROTAC Synthesis
ARD-69 is a PROTAC degrader based on the E3 ubiquitin ligase VHL and targeting the androgen receptor, which can induce androgen receptor (AR) protein degradation in AR-positive prostate cancer cells. ARD-69 inhibits AR-regulated gene expression, binds to the AR ligand binding domain at one end and binds to VHL at the other end, prompting AR to be recruited to the E3 ubiquitin ligase complex, triggering proteasome degradation, thereby inhibiting AR signaling pathways and downstream gene expression (such as PSA, TMPRSS2). ARD-69 can be used to study the treatment of castration-resistant prostate cancer (mCRPC) . ARD-69 is composed of a target protein ligand (pink part) AR antagonist 14 (HY-172624), a PROTAC linker (black part) tert-Butyl 4-ethynyl-[1,4'-bipiperidine]-1'-carboxylate (HY-W442074), and a VHL-type E3 ubiquitinase ligand (blue part) VH 101, acid (HY-47070); among them, the VHL ligand and the linker can form a conjugate VH 101-amide-piperidine-Pip-alkyne (HY-172625).

HY-151792

Pomalidomid-C6-PEG3-butyl-N3		PROTAC Synthesis Azide
Pomalidomid-C6-PEG3-butyl-N3 is a click chemistry reagent containing an azide group. Pomalidomid-C6-PEG3-butyl-N3 also is a crosslinker-E3 ligase ligand conjugate, which be used in click reactive protein degrader building block for PROTAC research. Pomalidomid-C6-PEG3-butyl-N3 also can be used in the template for synthesis of targeted protein degrader . It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

HY-108374

4-Azidobutylamine		Azide PROTAC Synthesis
4-Azidobutylamine is a PROTAC linker, which refers to the alkyl chain composition. 4-Azidobutylamine can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins . 4-Azidobutylamine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-151791

(S,R,S)-AHPC-C6-PEG3-butyl-N3		Azide
(S,R,S)-AHPC-C6-PEG3-butyl-N3 is a click chemistry reagent containing an azide group. (S,R,S)-AHPC-C6-PEG3-butyl-N3 serves as crosslinker-E3 ligase ligand conjugate, Click reactive protein degrader building block for PROTAC research, Template for synthesis of targeted protein degrader, VH032 conjugate . (S,R,S)-AHPC-C6-PEG3-butyl-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name		Classification

HY-118874A

Oblimersen sodium		Antisense Oligonucleotides
Oblimersen sodium is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen sodium specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen sodium can be used for cancer research .

HY-147266

Elebsiran sodium VIR-2218 sodium		siRNAs siRNA drugs
Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections .

HY-148503

5'-ODMT cEt N-Bz A Phosphoramidite (Amidite)		Nucleoside Phosphoramidites Adenine
5'-ODMT cEt N-Bz A Phosphoramidite (Amidite) is a nucleoside phosphoramidite monomer used to synthesize locked nucleic acid (LNA) analog oligonucleotides. It can be used as a building block of antisense oligonucleotides (ASOs) to target complementary RNA sequences. 5'-ODMT cEt N-Bz A Phosphoramidite (Amidite) locks the furanose ring into an N-type conformation through 2',4'-constrained ethyl (cEt) modification, enhancing hybridization affinity and mismatch discrimination with RNA, while significantly improving the resistance of oligonucleotides to exonuclease digestion. 5'-ODMT cEt N-Bz A Phosphoramidite (Amidite) mediates RNase H-dependent mRNA degradation or inhibits translation by forming a stable hybrid with RNA, thereby achieving gene expression regulation. 5'-ODMT cEt N-Bz A Phosphoramidite (Amidite) is mainly used in the development of antisense drugs, gene function research and oligonucleotide synthesis related to disease treatment .

HY-177453

Basivarsen DYNE-101 oligomer		Antisense Oligonucleotides
Basivarsen (DYNE-101 oligomer) is composed of an antisense oligonucleotides and a linker (HY-177454). It is designed to target mutant nuclear myotonic dystrophy protein kinase (DMPK) RNA for RHase H-mediated degradation to correct splicing. It is used for the study of myotonic dystrophy type 1 (DM1).

HY-118874

Oblimersen		Antisense Oligonucleotides
Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Targeted Degradation

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products